WASHINGTON, April 18 – In a move that signals a notable shift in federal health policy, U.S. President Donald Trump signed an executive order on Saturday aimed at accelerating research and access to treatments derived from psychedelic substances. The directive focuses particularly on ibogaine, a compound that has drawn growing attention for its potential role in addressing post-traumatic stress disorder and other mental health conditions.
Announced during a gathering at the White House, the order calls on federal agencies to reduce bureaucratic delays and prioritize scientific evaluation of certain substances that have long remained restricted under U.S. drug laws. The initiative also includes a $50 million commitment toward research into ibogaine, reflecting increasing interest among policymakers and health officials in alternative therapies.
Push to Expedite Research and Regulatory Review
At the center of the executive order is a directive to the U.S. Food and Drug Administration to accelerate its review process for ibogaine and similar compounds. FDA Commissioner Marty Makary indicated during the announcement that preliminary decisions regarding the drug’s medical potential could emerge as early as this summer, suggesting a significantly compressed timeline compared to traditional approval pathways.
Ibogaine, which is derived from a plant native to Central Africa, is currently classified as a Schedule I substance under the Drug Enforcement Administration’s guidelines. This classification places it in the same category as drugs considered to have no accepted medical use and a high potential for abuse. However, advocates argue that recent studies and anecdotal evidence, particularly among military veterans, justify reconsidering its status.
Health and Human Services Secretary Robert F. Kennedy Jr., who has publicly supported exploring unconventional treatments for mental health disorders, described the initiative as a necessary step toward addressing what he called a “growing crisis” in psychological care. He emphasized that traditional approaches have not been sufficient for many patients, especially those dealing with trauma-related conditions.
During the signing event, President Trump acknowledged that awareness of ibogaine has increased significantly over the past year. He noted that conversations with public figures, including podcast host Joe Rogan, played a role in bringing attention to the issue. Rogan, who attended the ceremony, has previously featured discussions on his platform highlighting the experiences of veterans who have sought treatment abroad.
The administration’s decision reflects a broader trend of reconsidering substances once viewed as strictly illicit. In late 2025, Trump signed a separate order supporting expanded research into marijuana and cannabidiol, another indication of shifting federal attitudes toward controlled substances.
Growing Support and Legislative Efforts
Beyond the executive branch, lawmakers from both political parties are beginning to rally behind the push for expanded access to psychedelic therapies. Representative Morgan Luttrell of Texas, who appeared alongside the president during the announcement, has been among the most vocal proponents. A former Navy SEAL, Luttrell has spoken about the struggles faced by veterans and the limitations of existing treatment options.
In a joint statement released after the signing, Luttrell and fellow Texas Republican Representative Michael McCaul said they plan to introduce legislation that would build on the executive order. Their proposal is expected to focus on easing restrictions, increasing funding for clinical trials, and creating clearer pathways for patients to access approved therapies.
“Our veterans answered the call when the nation needed them,” the statement read. “Now it is our responsibility to ensure they receive the care and support they deserve.”
Support for the initiative has also emerged from across the aisle. Representative Lou Correa, a Democrat from California, publicly endorsed the move, suggesting that early indications point to promising outcomes. Writing on social media, Correa called for further research and emphasized the importance of reclassifying substances like ibogaine to facilitate scientific study.
Meanwhile, international examples continue to shape the conversation. In countries where regulatory frameworks are less restrictive, ibogaine has already been used in clinical or semi-clinical settings. Mexico, in particular, has become a destination for treatment centers that attract patients from the United States, including veterans seeking alternatives not available at home. These cross-border experiences have added urgency to calls for domestic reform.
Federal officials acknowledged that while early findings are encouraging, significant scientific work remains. Clinical trials, safety evaluations, and standardized treatment protocols will all play a role in determining whether ibogaine can move from experimental status to an approved medical option.
Still, Saturday’s executive order marks a turning point in how the U.S. government approaches psychedelic research. What was once considered a fringe topic is increasingly entering mainstream policy discussions, driven by both public demand and evolving scientific perspectives.
As the FDA moves forward with its review and lawmakers prepare new legislative proposals, the coming months are likely to shape the future of psychedelic therapies in the United States. Whether ibogaine ultimately gains approval or not, the debate surrounding its use has already begun to reshape conversations about mental health treatment and drug policy at the highest levels of government.